Joe, this is what you are missing on SGNC:
News November 4, 06:11 Eastern Time
PASADENA, CALIF. (Nov. 4) BUSINESS WIRE -Nov. 4, 1998--Sanguine Corp.
(OTC BB: SGNC) Wednesday released findings of a major scientific breakthrough in
the development of its synthetic blood substitute, PHER-02.
Research scientists in the current program for Sanguine at Battelle Memorial Institute
(BMI) have developed five "novel" drug compounds to date that have "camouflage
characteristics" which extend the effective life of the compounds in the body and prevent
the body from rejecting a synthetic substance.
"The great significance of this breakthrough cannot be overstated," commented Sanguine
President and Chief Executive Officer Thomas C. Drees, Ph.D. "Prior to this initial
finding by Battelle, we already knew about 150 possible end-use applications for
PHER-02. This recent research suggests that the number of applications could be
greatly expanded. Finally, this breakthrough improves the overall patentability of the
product."
Battelle's findings address problems found in earlier products as well as those of current
competitor products, according to Drees. The limitation of short lifetime within the body
would significantly restrict the type of procedures for which a blood substitute could be
used. BMI chemists have conceived "novel" compounds that are expected to increase
lifetimes in the bloodstream and allow the benefit of prolonged oxygen delivery to the
patient.
In its report to Sanguine, BMI also states its objective to establish the dates of Battelle's
inventions and provide patent protection for the compounds and methodologies
prepared and developed for Sanguine.
Battelle is the world's largest independent contract research group of scientists,
engineers, and other specialists. Its scientists have provided research since 1994 in
support of Sanguine's efforts to develop, manufacture and market a proprietary
synthetic red blood cell substitute.
"Sanguine estimates the annual worldwide market potential for a synthetic red blood cell
substitute at $20 billion," stated Drees. "In the United States alone, nearly everyone who
reaches the age of seventy-five will need blood, plasma, or one of their components at
least once in his lifetime."
Drees, who has been in the forefront of the artificial blood products field for more than
20 years, was the president and CEO of the only company to have obtained FDA
approval for a synthetic blood product to date.
For appropriate risk factors please refer to the 10SB Registration Statement previously
filed by the company with the Securities & Exchange Commission at www.sec.gov.
|
